- Home
- CANF
CANF
Can-Fite Biopharma Ltd Sponsored ADR (Israel)
as 03-26-2025 12:31pm EST
Upcoming Earnings Alert:
Get ready for potential market movements as Can-Fite Biopharma Ltd Sponsored ADR (Israel) CANF prepares to release earnings report on 01 Apr 2025.
| Founded: | 1994 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 352.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.29 - $4.69 | Next Earning Date: | 04-01-2025 |
| Revenue: | $667,000 | Revenue Growth: | -15.89% |
| Revenue Growth (this year): | 409.56% | Revenue Growth (next year): | N/A |
Latest Can-Fite Biopharma Ltd Sponsored ADR (Israel) News
CANF Breaking Stock News: Dive into CANF Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication
GlobeNewswire
3 days ago
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
GlobeNewswire
7 days ago
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
GlobeNewswire
8 days ago
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
MT Newswires
9 days ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
9 days ago
Sector Update: Health Care Stocks Edge Down in Afternoon Trading
MT Newswires
9 days ago
Can-Fite Says US FDA Approves Compassionate Use Treatment With Namodenoson in Pancreatic Cancer Patient
GlobeNewswire
9 days ago
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
Compare CANF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.